Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,140 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Flu Clear all
Completed Not applicable Interventional Results available

The Respiratory Protection Effectiveness Clinical Trial

NCT01249625
View directory record Official record
Conditions
Influenza, Respiratory Syncytial Viruses, Paramyxoviridae Infections, Coronavirus, Rhinovirus
Interventions
N95 Respirator, Medical/surgical mask
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
2,862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
7
States / cities
Aurora, Colorado • Denver, Colorado • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma

NCT02814643
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Benralizumab Placebo, Seasonal influenza virus vaccine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 21 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Birmingham, Alabama • Mesa, Arizona • Huntington Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 23, 2026, 3:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-Based Study Platform

NCT04663776
View directory record Official record
Conditions
Covid19, Influenza, Respiratory Tract Infections, Acute Respiratory Tract Infection, Acute Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
16,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 23, 2026, 3:53 PM EDT
Recruiting Phase 1 Interventional

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

NCT04697576
View directory record Official record
Conditions
Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Interventions
Ipilimumab, Nivolumab, Pembrolizumab, Quadrivalent Inactivated Influenza Vaccine, Resection, Nivolumab + Relatlimab
Biological · Procedure
Lead sponsor
Carlo Contreras
Other
Eligibility
18 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 23, 2026, 3:53 PM EDT
Terminated No phase listed Observational Results available

Clinical Validation of the Point-of-Care MSD Influenza Test

NCT00863343
View directory record Official record
Conditions
Influenza Human
Interventions
Public Health Notification
Biological
Lead sponsor
Meso Scale Diagnostics, LLC.
Industry
Eligibility
Not listed
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
San Diego, California • Lebanon, New Hampshire • Port Jefferson, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

NCT04789577
View directory record Official record
Conditions
Influenza, Human
Interventions
FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3, AS03B, AS03A, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
833 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
8
States / cities
Stockbridge, Georgia • Meridian, Idaho • Cary, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Intranasal AD4-H5-VTN as an Adenovirus Vaccine

NCT01806909
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ad4-H5-Vtn
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 23, 2026, 3:53 PM EDT
Completed No phase listed Observational

Ovarian Cancer and Immune Response to Flu Vaccine

NCT00478387
View directory record Official record
Conditions
Ovarian Cancer
Interventions
The current season's trivalent killed influenza vaccine
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Not applicable Interventional Results available

Patient Portal Reminder/Recall for Influenza Vaccination in a Health System- RCT 2

NCT04110314
View directory record Official record
Conditions
Influenza, Respiratory Tract Infections
Interventions
Portal Reminders for Influenza Vaccination: Gain-framed, Portal Reminders for Influenza Vaccination: Loss-framed, Pre-commitment prompt
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
4 Months and older
Enrollment
430,636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 23, 2026, 3:53 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2

NCT06848309
View directory record Official record
Conditions
Influenza, SARS-CoV-2 (COVID-19) Infection, Immune Response of Host
Interventions
Bronchoscopy
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pandemic Influenza Plasmid DNA Vaccines (Needle)

NCT00709800
View directory record Official record
Conditions
Influenza
Interventions
VCL-IPT1, VCL-IPM1, PBS
Biological
Lead sponsor
Vical
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
3
States / cities
San Diego, California • Baltimore, Maryland • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2009 · Synced Oct 23, 2026, 3:53 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

SCID Bu/Flu/ATG Study With T Cell Depletion

NCT02127892
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
unrelated BM with T cell depletion, unrelated cord blood, haplo BM with T cell depletion, unrelated PBSC with T cell depletion
Biological · Device
Lead sponsor
Neena Kapoor, M.D.
Other
Eligibility
Up to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Kent State University / Price Chopper Employee Wellness Study

NCT03454009
View directory record Official record
Conditions
Acute Respiratory Infection, Influenza-like Illness, Gastrointestinal Infection
Interventions
Multimodal hygiene intervention
Behavioral
Lead sponsor
Kent State University
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Schenectady, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

FLU-FIT Program at Kaiser Permanente Northern California

NCT01210235
View directory record Official record
Conditions
Colorectal Cancer Screening
Interventions
FLU-FIT Program
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 75 Years
Enrollment
7,465 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 23, 2026, 3:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults

NCT03743688
View directory record Official record
Conditions
Influenza, Influenza, Human, Vaccine Reaction, Influenza A, Influenza Type B, Influenza A H1N1, Influenza A H3N2
Interventions
Influenza Vaccine Recipients
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects

NCT03345043
View directory record Official record
Conditions
Influenza
Interventions
VAL-339851, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children

NCT00391391
View directory record Official record
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
Split, Inactivated, Trivalent Influenza Vaccine, Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)
Biological
Lead sponsor
Sanofi
Industry
Eligibility
6 Months to 8 Years
Enrollment
520 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
19
States / cities
Harrisburg, Arkansas • Little Rock, Arkansas • Trumann, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2011 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Phase 1 Interventional Results available

Safety Study to Evaluate FluMist in Immunocompromised Children

NCT00112112
View directory record Official record
Conditions
Cancer
Interventions
FluMist, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
5 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
Rochester, New York • Stony Brook, New York • Memphis, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

FLU-VACS Comparative Study in Adults

NCT00133523
View directory record Official record
Conditions
Influenza
Interventions
Cold-adapted live attenuated influenza virus vaccine, trivalent, Placebo, Trivalent inactivated influenza vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
2,349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
6
States / cities
Ann Arbor, Michigan • Kalamazoo, Michigan • Livonia, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults

NCT04896086
View directory record Official record
Conditions
Influenza, Seasonal Influenza
Interventions
VRC-GENADJ0110-AP-NV (Adjuplex), Flucelvax, VRC-FLUMOS0111-00-VP (FluMos-v1)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Not applicable Interventional Results available

A Digital Flu Intervention for People With Cardiovascular Conditions

NCT04584645
View directory record Official record
Conditions
Cardiovascular Diseases, Atrial Fibrillation, Abnormal Heart Rhythms, Cardiac Arrest, Heart Attack, Myocardial Infarction, Coronary Heart Disease, Heart Failure, Stroke, Cerebrovascular Accident
Interventions
Targeted digital intervention
Other
Lead sponsor
Evidation Health
Industry
Eligibility
18 Years and older
Enrollment
49,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 23, 2026, 3:53 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

NCT05567783
View directory record Official record
Conditions
Influenza A
Interventions
VIR-2482 (450 mg), VIR-2482 (1200 mg), Placebo
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
2,977 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
51
States / cities
Anniston, Alabama • Mobile, Alabama • Tempe, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older

NCT06744205
View directory record Official record
Conditions
Influenza, Healthy Volunteers
Interventions
Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1, TIV mRNA-neuraminidase (NA), TIV mRNA-HA Vaccine 2, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza Vaccine High Dose
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years and older
Enrollment
1,162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
21
States / cities
Birmingham, Alabama • Mobile, Alabama • Tempe, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 23, 2026, 3:53 PM EDT
Completed No phase listed Observational

Influenza Vaccine in Lung Transplant Patients - Antibody

NCT04533139
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 23, 2026, 3:53 PM EDT